India's First Indigenous Dengue Vaccine Nears Reality: Panacea Biotec Shares Surge

• Panacea Biotec's shares surged after completing Phase-III enrolment for its indigenous dengue vaccine, DengiAll.
• DengiAll aims to protect against all four dengue strains in a single dose, with a potential launch by 2027.
• India faces a severe dengue epidemic, with cases rising to 2.33 lakh in 2024, accounting for 30% of global cases.
• The trial involved 10,335 people, who will be monitored for two years to assess the vaccine's efficacy and safety.
• This indigenous vaccine, under development since 2008, could be a major game-changer for India's healthcare system.

Why It Matters: Panacea Biotec's indigenous dengue vaccine offers major hope for India's escalating dengue crisis.